ReviewNature reviews. Clinical oncology2018
Accelerating anticancer drug development - opportunities and trade-offs.
Review in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Augmenting randomized clinical trial data with historical control data: Precision medicine applications.Journal of the National Cancer Institute · 2023Trial
- Dynamic clinical trial success rates for drugs in the 21st century.Nature communications · 2025Article
- Dose response test of patient-derived cancer organoids to irradiation.Frontiers in oncology · 2025Article
- Use of Bayesian approaches in oncology clinical trials: A cross-sectional analysis.Frontiers in pharmacology · 2025Article
- AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer.Nature communications · 2024Article
- Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates.FEBS open bio · 2024Article
- Spheroids and organoids derived from colorectal cancer as tools forExploration of targeted anti-tumor therapy · 2024Review
- Article
- Design a Clinical Research Protocol: Influence of Real-World Setting.Healthcare (Basel, Switzerland) · 2023Review
- Natural fulvic acids inhibit non-small-cell lung cancer through the COX-2/PGE2/EP4 axis: In silico and in vivo assessments.Heliyon · 2023Article
- Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment.Biomedicines · 2023Review
- Association between control group therapy and magnitude of clinical benefit of cancer drugs.Scientific reports · 2022Article
- Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review.Journal of clinical medicine · 2022Review
- Anticancer activity and QSAR study of sulfur-containing thiourea and sulfonamide derivatives.Heliyon · 2022Article
- Article
- Reconstructing the tumor architecture into organoids.Advanced drug delivery reviews · 2021Review
- Review
- Bioinformatic Approaches to Validation and Functional Analysis of 3D Lung Cancer Models.Cancers · 2021Review
- Coherent Raman Scattering Microscopy in Oncology Pharmacokinetic Research.Frontiers in pharmacology · 2021Review
- Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The traditional approach to drug development in oncology, with discrete phases of clinical testing, is becoming untenable owing to expansion of the precision medicine paradigm, whereby patients are stratified into multiple subgroups according to the underlying cancer biology. Seamless approaches to drug development in oncology hold great promise of accelerating the accessibility of novel therapeutic agents to the public but are also accompanied by important trade-offs, including the limited availability of information on the clinical benefit and safety of novel agents at the time of market entry. In this Perspectives article, we describe several opportunities, in the form of novel trial designs or modelling strategies, to improve the efficiency of drug development in oncology, as well as new mechanisms to obtain information about anticancer therapies throughout their life cycle, such as innovative functional imaging techniques or the use of real-world clinical data.
Indexed as
Identifiers
30275514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.